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Abstract We have isolated and characterized from human
prostate novel splice variants of the human K1A-adrenoceptor,
several of which generate truncated products and one isoform,
K1Aÿ4, which has the identical splice site as the three previously
described isoforms. Long-PCR on human genomic DNA showed
that the K1Aÿ4 exon is located between those encoding the K1Aÿ1
and K1Aÿ3 variants. CHO-K1 cells stably expressing K1Aÿ4
showed ligand binding properties similar to those of the other
functional isoforms as well as agonist-stimulated inositol
phosphate accumulation. Quantitative PCR analyses revealed
that K1Aÿ4 is the most abundant isoform expressed in the
prostate with high levels also detected in liver and heart.
z 1998 Federation of European Biochemical Societies.
Key words: K1-Adrenoceptor; Splice variant; cDNA cloning;
Genome organization; Expression
1. Introduction
Alpha1-adrenoceptors are G-protein coupled transmem-
brane receptors which mediate various actions of the periph-
eral sympathetic nervous system through the binding of the
catecholamines, epinephrine and norepinephrine [1,2]. Molec-
ular cloning has identi¢ed three subtypes of the K1-adrenocep-
tor class in several species including human [3^6], and these
have been classi¢ed as K1A- (previously K1C-), K1B- and K1D-
adrenoceptors [7]. A putative fourth subtype, the K1L-adreno-
ceptor, which has low a⁄nity for the antagonist, prazosin, has
been de¢ned in functional but not in molecular studies. The
K1L-adrenoceptor is postulated to mediate the contraction of
several lower urinary tract tissues, including the smooth
muscle in the human prostate, suggesting a role for this sub-
type in the bladder outlet obstruction observed in patients
with benign prostatic hypertrophy [8,9].
Recent in-house data have shown that the cloned human
K1A-adrenoceptor exhibits the pharmacological pro¢le of the
K1L-adrenoceptor in functional studies but not in ligand bind-
ing studies [10]. These observations suggest that the K1A-adre-
noceptor gene may encode gene products that exhibit both the
K1A and K1L pharmacology. In addition, Tsujimoto and col-
leagues [11] have identi¢ed in human prostate two isoforms of
the K1A-adrenoceptor cDNA generated by alternative splicing,
which di¡er from the ‘original’ K1A-adrenoceptor cDNA in
length and sequence at the carboxy-terminal region. Follow-
ing the nomenclature for K1-adrenoceptors recommended by
the Nomenclature Committee of the International Union of
Pharmacology (NC-IUPHAR) [7,12], these isoforms are
named K1Aÿ1, K1Aÿ2 and K1Aÿ3. In this paper we describe
the identi¢cation of additional K1A-adrenoceptor splice var-
iants from human prostate, many of which give rise to trun-
cated products, and also a fourth isoform containing a unique
carboxy-terminus, K1Aÿ4. In addition, we have localized the
‘isoform-speci¢c’ exons on human genomic DNA and exam-
ined functional expression and tissue distribution of these iso-
forms.
2. Materials and methods
2.1. cDNA library construction and screening
Two RNA sources were used to prepare the cDNA library, one
from a freshly frozen non-tumor prostate tissue collected from a pa-
tient undergoing radical prostatectomy, and the other from commer-
cially obtained human prostate mRNA (Clontech, Palo Alto, CA).
The cDNA was ligated into lambda ZAP II vector and packaged
with Gigapack Gold packaging extract (Stratagene, La Jolla, CA).
3.5U106 recombinant clones were screened with a 1.3 kbp HindIII
fragment of the published human K1A-adrenoceptor cDNA [3]. Hy-
bridization was carried out according to standard procedures [13].
Positive phage clones were converted into phagemids by in vivo ex-
cision and coinfection of the R408 helper phage (Stratagene). Nucleo-
tide sequence analysis was performed on the ABI 373A DNA Se-
quencer (Applied Biosystems, Foster City, CA) and determined on
both DNA strands.
2.2. PCR isolation of K1A-adrenoceptor isoforms
A sense primer derived from nucleotides 753^775 (5P-CAAGAC-
CAAGACGCACTTCTCAG-3P) in the third cytoplasmic loop region
between transmembrane domains V and VI and antisense primers
consisting of random hexamer oligonucleotides were used to generate
PCR products from human prostate Quickclone cDNA (Clontech).
PCR conditions consisted of denaturation at 94‡C for 1 min, anneal-
ing at 55‡C for 2 min and extension at 72‡C for 3 min for 35 cycles.
Fragments greater than 1 kbp in length were subcloned in PCR II
vector (Invitrogen, San Diego, CA) and subjected to sequence analy-
sis. The full-length coding sequence of the K1Aÿ3-adrenoceptor was
constructed by ligating the 5P portion of the K1Aÿ1-adrenoceptor
cDNA with the PCR-generated 3P fragment of the K1Aÿ3-adrenocep-
tor.
2.3. Quantitative PCR analysis
Expression levels of the K1A-adrenoceptor isoforms were quanti-
tated by competitive PCR using Quickclone cDNAs from human
heart, kidney, liver and prostate as templates. PCR ampli¢cation of
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the targets was performed in the presence of truncated versions of the
target (v standards) which contained excisions of 50^100 bp in the
regions £anked by the PCR primers. The sequences of the primers are
as follows: sense K1Aÿ1=ÿ2=ÿ3 : 5P-GCATCGTGGTCGGCTGCTTC-
GTCCTCTGCTG-3P ; sense K1Aÿ4 : 5P-CTAGAATGCTGATCTCC-
AGGT-3P ; antisense K1Aÿ1 : 5P-TCTTTCCTGTCCTAGACTTCCT-
CC-3P ; antisense K1Aÿ2 : 5P-CACCAGTCACCATGGAGAGAATG-
3P ; antisense K1Aÿ3 : 5P-AGGACAACAGTCGTGGACG-3P ; anti-
sense K1Aÿ4 : 5P-CTCCTGAGCCACACGAAAAG-3P. PCR products
were run on 1% agarose gel, stained with ethidium bromide and
analyzed on a molecular imager (PDI). The ratio between each am-
pli¢ed cDNA/v standard was used as the amount of mRNA present
for each isoform.
2.4. Determination of genomic organization
PCR on human genomic DNA was performed using a sense primer
corresponding to the common transmembrane domain VII region of
the K1A-adrenoceptor from nucleotides 981^1000 (5P-ATGCTC-
CAGCCAAGAGTTCA-3P), a sense primer in K1Aÿ4 (5P-CCA-
GAATGCTGATCTCCAGGT-3P), and antisense primers in K1Aÿ4
(5P-CTCCAGCTACCTGGAGATCAG-3P) and K1Aÿ3 (5P-TCATGT-
CATGGGTGTGTGTC-3P). Products were run on agarose gels and
the lengths were estimated by standard markers. The length of the
intron between K1Aÿ1 and K1Aÿ4 exonic sequences was con¢rmed by
DNA sequencing.
2.5. Stable expression cell lines
The cloned K1A-adrenoceptor isoform cDNAs were ligated into
pSW104 expression vector which contains the SR-K promoter [14]
and Bluescript KS plasmid multiple cloning site. The constructs
were co-transfected with a pSV2neo plasmid into CHO-K1 cells using
the lipofection method [15]. The cells were grown in Ham’s F12 me-
dium (Gibco-BRL, Gaithersburg, MD), supplemented with 10% fetal
bovine serum and penicillin/streptomycin (30 U/ml, 30 Wg/ml) at 37‡C
in 5% CO2. Stable single clones were selected for resistance to G418 at
400 Wg/ml concentration, expanded and harvested for radioligand
binding and functional studies.
2.6. Radioligand binding assay
Cells were lysed by Polytron (Brinkman, New York, NY) homog-
enization in ice-cold 50 mM Tris-HCl, 5 mM EDTA pH 7.4 bu¡er.
The lysate was centrifuged and the pelleted membrane was resus-
pended in 50 mM Tris-HCl, 0.5 mM EDTA pH 7.4 bu¡er. The mem-
branes were incubated with [3H]prazosin, speci¢c activity 82 Ci/mmol
(New England Nuclear, Boston, MA) for 60 min at 25‡C in the
presence or absence of competing drugs. Incubation was terminated
by vacuum ¢ltration through GF/B ¢lters pretreated with 0.1% poly-
ethyleneimine. Bound radioligand was counted using liquid scintilla-
tion spectroscopy.
2.7. Inositol phosphate assay
Inositol phosphate accumulation was determined using a modi¢ca-
tion of described procedures [16]. Cells were pre-loaded overnight
with [3H]myo-inositol (2 WCi/ml), washed and resuspended in inosi-
tol-free Ham’s medium. Antagonist was then added for 20 min at
37‡C followed by the addition of 2 WM norepinephrine with LiCl
(10 mM) and incubation at 37‡C for 10 min. Reactions were termi-
nated by addition of ice-cold perchloric acid (20% w/v) and neutral-
ized samples were decanted into a Dowex AG 1U8 (chloride form)
column and [3H]inositol phosphates were eluted for liquid scintillation
counting.
3. Results and discussion
Screening of a mixed human prostate cDNA library with a
1.3 kbp fragment comprising the coding sequence of the hu-
man K1A-adrenoceptor yielded a total of 28 positive clones.
DNA sequencing of all the clones revealed that they fall into
¢ve di¡erent classes. Several clones contained either full-
length coding or partial sequences identical to that of the
original published human K1A-adrenoceptor cDNA, the
K1Aÿ1 isoform [11]. Five clones were isolated and found to
contain sequences virtually identical to the K1Aÿ2 isoform ex-
cept at one position. A deletion of a G at position 1393 results
in a shift in the reading frame after amino acid residue 464
and introduces a stop codon following amino acid residue 475
(Fig. 1A). This nucleotide change was con¢rmed by sequenc-
ing both DNA strands from all the clones and the reason for
this di¡erence is unclear.
Two clones, #10 and #15, were identi¢ed to contain coding
sequences which terminate in transmembrane domain VI (Fig.
1A). Close examination of the nucleotide sequences reveals a
divergence occurring at position 883 which has been identi¢ed
as an intron/exon junction by Tseng-Crank and colleagues
[17] and suggests that these clones are generated through al-
ternative RNA splicing at the acceptor sites. Furthermore,
clone #15 contains one extra T residue between nucleotide
positions 866 and 867 resulting in a shift in reading frame,
which was also observed in human liver-derived K1A clones in
the aforementioned study [17].
Most interestingly, a 4.5 kbp clone, #13, was identi¢ed with
a nucleotide sequence identical to that of the published iso-
forms up to position 1269 (including all the transmembrane
domains) but followed by a novel sequence. Since this is also
the location where the published isoforms diverge in their
carboxy-terminal sequences, we believe clone #13 is a novel
isoform and have named it K1Aÿ4 (GenBank accession number
AF013261). The deduced amino acid sequence of K1Aÿ4 (Fig.
1B) reveals that it encodes a protein of 455 amino acids and
contains almost 1.7 kbp of 3P untranslated region. The unique
portion of the carboxy-terminal tail contains two Ser/Thr res-
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Table 1
Pharmacological pro¢les of human K1A-adrenoceptor isoforms
K1Aÿ1 K1Aÿ2 K1Aÿ3 K1Aÿ4
Prazosina 9.9 þ 0.0 9.7 þ 0.4 9.2 þ 0.2 9.8 þ 0.1
Tamsulosina 10.4 þ 0.2 10.5 þ 0.4 10.0 þ 0.1 10.4 þ 0.2
RS-17053a 9.2 þ 0.1 8.9 þ 0.4 8.8 þ 0.1 8.9 þ 0.0
WB 4101a 9.8 þ 0.1 9.6 þ 0.3 9.2 þ 0.2 9.4 þ 0.2
5-Me-urapidila 9.2 þ 0.1 8.9 þ 0.4 8.4 þ 0.2 9.0 þ 0.1
Prazosinb 8.7 þ 0.0 8.8 þ 0.1
Tamsulosinb 10.5 þ 0.1 10.1 þ 0.1
RS-17053b 8.2 þ 0.1 8.0 þ 0.4
WB 4101b 8.9 þ 0.1 8.5 þ 0.2
(+)Niguldipineb 8.4 þ 0.3 8.2 þ 0.1
aA⁄nities (pKi) of ligands for K1A-adrenoceptor isoforms. Data are the means þ S.E.M. (n = 3) from radioligand displacement experiments using
recombinant receptors expressed in CHO-K1 cells.
bA⁄nity estimates (pKb) of ligands for K1Aÿ1 and K1Aÿ4 receptors. Data are the means þ S.E.M. (n = 3) from antagonist inhibition curves obtained
against (3)norepinephrine-stimulated [3H]inositol phosphate accumulation in CHO-K1 cells expressing the isoforms.
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idues as compared to nine in the unique portion of K1Aÿ1, 12
in K1Aÿ2 and two in K1Aÿ3. Whether any of these residues are
sites of phosphorylation which might dictate di¡erences in
down-regulation of the isoforms is not known.
Since we did not isolate the K1Aÿ3 isoform from screening
the prostate lambda phage cDNA library and because there
may be additional K1A-adrenoceptor isoforms, we performed
PCR on prostate cDNA with random and isoform-speci¢c
primers. Using this method, we successfully isolated K1Aÿ3
and also identi¢ed two more isoforms which encode truncated
proteins. Both clones #11 and #21 (Fig. 1A) show sequence
divergence following the intron/exon junction in transmem-
brane domain VI. Clone #11 contains a 180 bp insert with
an in-frame stop codon after which the sequence matches that
of K1Aÿ1 (data not shown). A human hippocampus-derived
K1A-adrenoceptor clone (1088-7) with similar if not identical
sequence has been previously described [17]. In contrast, clone
#21 utilizes the same splice acceptor site as K1Aÿ2 (data not
shown) but with a shift in reading frame which results in a
di¡erent amino acid sequence.
To determine the genomic organization of the exon cas-
settes which contain the unique 3P sequences of the non-trun-
cated isoforms (K1Aÿ1=ÿ2=ÿ3=ÿ4), human genomic DNA was
subjected to long-range PCR analysis. PCR using a sense
primer from the common transmembrane domain VII se-
quence and antisense primers in the unique sequences for
K1Aÿ4 and K1Aÿ3 yielded products with sizes of approximately
4.5 kbp and 13 kbp, respectively (Fig. 2A). The distance be-
tween K1Aÿ4 and K1Aÿ3 was also deduced when a 9 kbp prod-
uct was generated in the PCR reaction with sense primer in
the K1Aÿ4 sequence and antisense primer in the K1Aÿ3 se-
quence. Direct sequencing of genomic DNA by primer walk-
ing con¢rmed the locations of the exon cassettes for K1Aÿ1,
K1Aÿ4 and K1Aÿ3 as well as the lengths of the introns (Fig.
2C). The exact length of the K1Aÿ3 exon cassette could not be
determined because this clone was derived by PCR.
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Fig. 1. A: Deduced carboxy-terminal amino acid sequences of truncated K1A-adrenoceptor isoforms isolated from human prostate cDNA. The
corresponding amino acid sequences of K1Aÿ1, K1Aÿ2 (di¡erences from published sequence are underlined) and K1Aÿ3 receptors are also shown.
B: Nucleotide (top) and amino acid (bottom) sequences of the carboxy-terminal region of K1Aÿ4 which di¡ers from the three other functional
isoforms. The nucleotide and amino acid positions (from the translation start site) are shown at both ends.
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Attempts to localize the K1Aÿ2 exon cassette by PCR using
K1Aÿ2-speci¢c primers were unsuccessful. Close examination
of the unique 3P sequence of this isoform reveals a very
high homology to the Alu-Sc gene family (Fig. 2B) which
are interspersed throughout the human genome [18]. Although
the presence of an Alu element in an open reading frame
could be the result of an artifact from cDNA cloning, we
do not believe K1Aÿ2 was generated this way for two reasons.
First, the splice site is identical to that for K1Aÿ3 and K1Aÿ4.
Second, K1Aÿ2 can be identi¢ed from both cDNA library
screening and PCR ampli¢cation of tissue mRNA (described
below). Since Alu elements can be actively transcribed by
RNA polymerase III, the splicing mechanism in the genera-
tion of K1Aÿ2 may not necessarily involve an intramolecular
reaction (cis-splicing) but an intermolecular splicing of exons
between two di¡erent RNAs (trans-splicing), which has been
observed more commonly in genes in lower organisms and in
mitochondria [19,20].
All the newly isolated K1A-adrenoceptor isoforms were tran-
siently expressed in Cos-7 cells and tested for ligand binding
activities. As expected, K1Aÿ4 displayed appropriate binding
a⁄nity to [3H]prazosin but none of the truncated isoforms
(#10, 11, 15, 21) exhibited any speci¢c radioligand binding
(data not shown). It is not known, however, whether these
truncated isoforms are actually expressed on the plasma mem-
brane following transient transfection and so we cannot state
that the generated products are non-functional.
Next, the pharmacological pro¢les of the recombinant
K1Aÿ1-, K1Aÿ2-, K1Aÿ3- and K1Aÿ4-adrenoceptors, stably ex-
pressed in CHO-K1 cells, were compared using radioligand
binding. In addition, functional estimates of a⁄nity were de-
termined for several ligands at the K1Aÿ1- and K1Aÿ4-adreno-
ceptors by measuring antagonism of (3)norepinephrine-
stimulated accumulation of inositol phosphates. As seen in
Table 1, binding studies showed that all four isoforms display
the classical K1A-adrenoceptor pro¢le (subnanomolar a⁄nities
for prazosin and WB4101) with similar a⁄nities for all the
tested ligands. In functional studies, both K1Aÿ1- and K1Aÿ4-
adrenoceptors exhibited lower a⁄nities for prazosin and RS-
17053, indicative of K1L-adrenoceptor pharmacology. These
two receptors were virtually indistinguishable in their opera-
tional pro¢les (Table 1). Recent data have shown that K1Aÿ2-
and K1Aÿ3-adrenoceptors also demonstrate K1L-receptor phar-
macology in functional studies [21]. Interestingly, norepi-
nephrine also stimulates cyclic AMP accumulation in cells
transfected with the four adrenoceptor isoforms (S. Yama-
nishi and D. Daniels, unpublished observations) suggesting
that the K1A-adrenoceptor in a recombinant system can couple
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Fig. 2. A: PCR analysis of human genomic DNA using primers described in Section 2. Lanes are: (M) lambda HindIII marker, (1) common
TM VII sense primer with K1Aÿ4 antisense primer, (2) K1Aÿ4 sense primer with K1Aÿ3 antisense primer, (3) common TM VII sense primer with
K1Aÿ3 antisense primer. B: Comparison between the 3P sequence of K1Aÿ2 and the consensus Alu-Sc sequence (GenBank accession number
U14571). The overall homology between the two sequences within this region is 87%. C: Genomic organization of the human K1A-adrenoceptor
isoforms. The top ¢gure is a schematic representation of the human K1A-adrenoceptor gene with boxes representing exons and lines representing
introns. The numbers below the boxes and lines represent approximate lengths of exons and introns in nucleotide base pairs. The bottom ¢gure
shows the location of splice sites, and the amino acid sequences at the amino-terminus, donor and acceptor sites, and at the carboxy-termini.
The full-size lengths of each splice variant product are shown in parentheses.
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to Gs in addition to Gq, an observation previously shown for
the hamster K1B-adrenoceptor [22].
The expression levels of the four functional isoforms in
human heart, kidney, liver and prostate were determined by
quantitative PCR with truncated constructs as internal stand-
ards. As seen in Fig. 3, total K1A-adrenoceptor mRNA level
was highest in the liver, followed by heart, prostate and kid-
ney. The abundance of each isoform varied in the di¡erent
tissues, with K1Aÿ1 showing the highest levels in liver and
heart. Interestingly, the newly identi¢ed K1Aÿ4 was the most
abundant isoform in the prostate and K1Aÿ1 was the least
abundant. This observation was rather surprising since the
prostate has been used in several studies to clone the human
K1A-adrenoceptor [3,5,11] and the K1Aÿ4 isoform has not been
identi¢ed until now. We did not measure mRNA levels of the
truncated isoforms except for clone #21 which showed ex-
tremely low (6 1 fM) amounts in all four tissues examined
(data not shown).
The physiological signi¢cance of K1A-adrenoceptor splice
variants is presently unknown. Since the four functional iso-
forms di¡er only in their carboxy-terminal regions, they may
di¡er in their preference for G-protein coupling as observed in
the isoforms of the prostaglandin EP3 receptor [23] or in rates
of desensitization mediated by phosphorylation as seen in the
K1B- [24] and L2- [25] adrenergic receptors. The role of the
truncated isoforms is equally if not more perplexing. Assum-
ing the truncated proteins reach the plasma membrane, the
possibility that there may be inter-receptor interactions, as
shown for the muscarinic receptors [26,27], which not only
restore function but also introduce novel pharmacology is
intriguing. Finally, the results of the mRNA expression study
raise the possibility that relative levels of the isoforms in a
tissue may change depending on its pathological state (for
example, normal vs. hyperplastic prostate) and provide a mo-
lecular explanation for the initiation or development of a dis-
ease.
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Fig. 3. mRNA levels of the four functional isoforms of the K1A-
adrenoceptor in the human heart, kidney, liver, and prostate. The
expression levels were estimated using truncated standards in com-
petitive PCR experiments and recalculated as femtomolar (fM) con-
centration of the target present in the cDNAs. Each value is an
average of two separate experiments with standard errors shown.
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